PMD Alliance

PMD Alliance is a 501c3 nonprofit organization dedicated to educating, empowering, and connecting people with movement disorders, their families, and the healthcare providers and community members who care for them.


Connect with us:

Latest from PMD Alliance


Interdisciplinary Care and Hot Topics in Movement Disorders: Jill Farmer, DO, MPH

June 25, 2022

The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute discussed the importance of a multidisciplinary approach to movement disorders and the hot topics of conversation at ATMRD. [WATCH TIME: 2 minutes]

The ATMRD Congress and Importance of Accessibility as a Clinician: Jill Farmer, DO, MPH

June 23, 2022

The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute spoke about her time at the 2022 ATMRD Congress and how successful communication between patients and providers is rooted in accessibility. [WATCH TIME: 2 minutes]

Apomorphine Sublingual Film Treatment for Parkinson Disease May Not Require Use of Antiemetics

June 20, 2022

After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.

IPX203 Design for Parkinson Disease Might Address Limitations of Current Oral Administrations of Levodopa

June 20, 2022

The pharmacodynamic and pharmacokinetic effects of the novel Amneal Pharmaceuticals therapy suggest that it can overcome the current absorption and exposure limitations of the oral levodopa therapies used to treat those with Parkinson disease motor fluctuations.

The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies

June 19, 2022

In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.